DK2490709T3 - Peptidiske glp-2-agonister - Google Patents

Peptidiske glp-2-agonister Download PDF

Info

Publication number
DK2490709T3
DK2490709T3 DK10825678.5T DK10825678T DK2490709T3 DK 2490709 T3 DK2490709 T3 DK 2490709T3 DK 10825678 T DK10825678 T DK 10825678T DK 2490709 T3 DK2490709 T3 DK 2490709T3
Authority
DK
Denmark
Prior art keywords
agonists
peptidic glp
peptidic
glp
Prior art date
Application number
DK10825678.5T
Other languages
English (en)
Inventor
Pierre Riviere
Sudarkodi Alagarsamy
Guangcheng Jiang
Claudio Daniel Schteingart
Javier Sueiras-Diaz
Kazimierz Wisniewski
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of DK2490709T3 publication Critical patent/DK2490709T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
DK10825678.5T 2009-10-23 2010-10-21 Peptidiske glp-2-agonister DK2490709T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25449009P 2009-10-23 2009-10-23
EP09173900A EP2314616A1 (en) 2009-10-23 2009-10-23 Peptidic GLP-2 agonists
PCT/US2010/053570 WO2011050174A1 (en) 2009-10-23 2010-10-21 Peptidic glp-2 agonists

Publications (1)

Publication Number Publication Date
DK2490709T3 true DK2490709T3 (da) 2015-01-05

Family

ID=41572524

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10825678.5T DK2490709T3 (da) 2009-10-23 2010-10-21 Peptidiske glp-2-agonister

Country Status (19)

Country Link
US (1) US8580918B2 (da)
EP (2) EP2314616A1 (da)
JP (1) JP5755653B2 (da)
KR (1) KR101794781B1 (da)
CN (1) CN102711802B (da)
AR (1) AR079877A1 (da)
AU (1) AU2010310665B2 (da)
CA (1) CA2777758C (da)
DK (1) DK2490709T3 (da)
ES (1) ES2530615T3 (da)
JO (1) JO3026B1 (da)
NZ (1) NZ599137A (da)
PL (1) PL2490709T3 (da)
PT (1) PT2490709E (da)
RS (1) RS53882B1 (da)
RU (1) RU2551977C2 (da)
SI (1) SI2490709T1 (da)
TW (1) TWI482627B (da)
WO (1) WO2011050174A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015160703A1 (en) * 2014-04-14 2015-10-22 Nps Pharmaceuticals, Inc. Treatment methods for gut-mediated hiv immune dysfunction
US20160067311A1 (en) * 2014-09-10 2016-03-10 Helsinn Healthcare Sa Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
US9783766B2 (en) 2015-04-03 2017-10-10 Ecolab Usa Inc. Enhanced peroxygen stability using anionic surfactant in TAED-containing peroxygen solid
HUE064463T2 (hu) 2016-07-11 2024-03-28 Opko Biologics Ltd Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
EP3412303A1 (en) * 2017-06-08 2018-12-12 Medizinische Universität Innsbruck Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
EP3517543B1 (en) * 2018-01-30 2020-11-04 Bachem AG Manufacture of glucagon peptides
US20200254065A1 (en) * 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
US20220257722A1 (en) * 2019-03-28 2022-08-18 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods of treating and preventing systemic complications of acute illness
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
GB202003762D0 (en) * 2020-03-16 2020-04-29 Heptares Therapeutics Ltd GLP receptor agonists
KR20220154691A (ko) * 2020-03-16 2022-11-22 헵테얼즈 테라퓨틱스 리미티드 경구 glp 수용체 작용제
WO2021198195A1 (en) 2020-03-30 2021-10-07 Zealand Pharma A/S Agonist combination
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
CN111560061A (zh) * 2020-05-26 2020-08-21 成都圣诺生物制药有限公司 一种Gelpaglutide的制备方法
KR20230038187A (ko) * 2020-06-09 2023-03-17 벡티브바이오 에이지 아프라글루타이드의 제조, 제형화 및 투여
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS
US20220233645A1 (en) 2021-01-28 2022-07-28 Vectivbio Ag Compositions and methods for the treatment of graft versus host disease
CN118005766B (zh) * 2023-06-21 2024-09-27 杭州信海医药科技有限公司 一种Glepaglutide的固相合成方法
WO2025208047A1 (en) 2024-03-28 2025-10-02 Vectivbio Ag Glucagon-like peptide 2 (glp-2) analogs for the treatment of graft versus host disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP0906338B1 (en) * 1996-04-12 2002-11-06 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US5994500A (en) * 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
ATE396202T1 (de) * 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
RU2005114512A (ru) * 2002-10-14 2006-12-27 Ново Нордиск А/С (DK) Варианты глюкагон-подобного пептида-2
MX2007013431A (es) * 2005-05-04 2008-01-18 Zealand Pharma As Analogos del peptido 2 semejante al glucagon.
AU2007319066B2 (en) * 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues

Also Published As

Publication number Publication date
EP2490709A1 (en) 2012-08-29
KR20120100942A (ko) 2012-09-12
RU2551977C2 (ru) 2015-06-10
ES2530615T3 (es) 2015-03-04
US20120231999A1 (en) 2012-09-13
JO3026B1 (ar) 2016-09-05
TWI482627B (zh) 2015-05-01
EP2490709B1 (en) 2014-11-26
JP2013508398A (ja) 2013-03-07
PT2490709E (pt) 2015-03-04
KR101794781B1 (ko) 2017-11-09
CA2777758C (en) 2018-06-05
CN102711802B (zh) 2017-03-22
NZ599137A (en) 2013-04-26
RU2012116046A (ru) 2013-11-27
SI2490709T1 (sl) 2015-04-30
RS53882B1 (sr) 2015-08-31
WO2011050174A1 (en) 2011-04-28
CA2777758A1 (en) 2011-04-28
AR079877A1 (es) 2012-02-29
AU2010310665A1 (en) 2012-05-03
EP2490709A4 (en) 2013-05-15
JP5755653B2 (ja) 2015-07-29
EP2314616A1 (en) 2011-04-27
PL2490709T3 (pl) 2015-04-30
US8580918B2 (en) 2013-11-12
TW201119668A (en) 2011-06-16
CN102711802A (zh) 2012-10-03
AU2010310665B2 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
NL301164I2 (nl) sacituzumab govitecan
PT2490709E (pt) Agonistas glp-2 peptídicos
HUE045331T2 (hu) Szikkasztótest
DK2430035T3 (da) Uracylspipooxetannukleosider
DE112010002728A5 (de) Turboinhalator
FI20086143A0 (fi) Pistorasia
DE112009005323A5 (de) Hebelarmprüfmaschine
BR112012004964A2 (pt) girocóptero
FI20095891A0 (fi) Polttomoottorisovitelma
EP2409976A4 (en) GLYCINE TRANSPORTER INHIBITOR
DK2516406T3 (da) Mglu2-agonister
DE112010003255A5 (de) Fördergutverteiler
DK2213923T3 (da) Drejeled
EP2518828A4 (en) Rfid tag
FI20090100A0 (fi) Biotinidaasimääritys
DE112010002351A5 (de) Klemmorrichtung
EP2392475A4 (en) NECESSARY TO PAINT
FI20096108A0 (fi) Järjestely
FI20090173A0 (fi) Pystypuun karsintalaite
ZA201202724B (en) Peptidic glp-2 agonists
UA19554S (uk) Трюмо
SMT201500065B (it) Agonisti peptidici del glp-2
UA20191S (uk) Плакат
ES1069777Y (es) Desatascador
UA19398S (uk) Рекламний щит